Hengrunda Sheng and Leap Technology's ChiNext IPO review status has been changed to "on hold (financial report updated)".

The official website of the Shanghai Stock Exchange shows that on June 30th, Hengrunda Sheng and Lai Pu Technology, a total of 2 companies' IPO review status on the Sci-Tech Innovation Board has been updated to "suspended (financial report update)". Lai Pu Technology focuses on advanced precision laser technology and semiconductor innovation process development as its core, mainly engaged in the research, development, production, and sales of high-end semiconductor special equipment, and provides related technical services. Lai Pu Technology always takes user demand as its guide, based on independent innovation, targeted research and development of advanced precision laser technology, innovative processes, and equipment for the semiconductor industry, and extends its layout to precision electronic manufacturing and MLED industries, thus constructing a complete supply system covering two product lines of laser heat treatment equipment and special laser processing equipment. Hengrunda Sheng is an innovative biopharmaceutical company that focuses on the research and production of breakthrough immunotherapy products, mainly focusing on the treatment of malignant blood diseases and solid tumors. Cancer immunotherapy using CAR-T as a representative is an international cutting-edge direction in cancer treatment and is currently considered one of the most promising methods to cure cancer, especially showing remarkable efficacy in patients with end-stage relapsed, refractory tumors who have shown no response to other treatments, significantly improving patients' clinical benefits.